Viral Vector Development Platforms
Viral vectors are virus-based gene vectors that can be used to deliver target genes into cultured cells or intact living organisms. As a reliable and trustworthy partner, our company has a diverse pool of talent, as well as professional knowledge and experience related to viral vectors. We are committed to using cutting-edge technologies in molecular biology and cell biology to provide comprehensive viral vector development services to our customers for rare disease therapy research and development.
Overview of Viral Vector
Viral vectors can carry genetic material into cells, either in vivo or in vitro. The principle is to use the molecular mechanism of viruses to transmit their genome into other cells for infection. The main types of viral vectors used clinically for in vivo gene therapy include adenovirus, adeno-associated virus (AAV), herpes simplex virus (HSV), retroviruses, and lentiviruses. Viral vectors used for gene therapy and vaccines should meet the following basic conditions:
- Mediates the transfer and expression of foreign genes.
- Don't cause proliferation and spread in the environment.
- Not pathogenic to humans.
- Carry foreign genes and can be packaged into virus particles.
Fig.1 Viral vector manufacturing process workflow. (Srivastava, A., et al., 2021)
Viral Vector for Rare Diseases
In many cases, gene therapy requires a vector to deliver the gene therapy drug to the target cell. Viral vectors have been one of the most widely studied vectors due to their outstanding transduction efficiency and other significant advantages. Viral vector-based gene therapy has now achieved good research results. The following are some of the viral vectors that have been heavily used for gene therapy of rare diseases:
Table 1 Commonly used viral vectors in rare disease gene therapy. (Maldonado, R., et al., 2021)
| Vector | Transfection capacity | Integration | Restrictions |
|---|---|---|---|
| Adenovirus | < 7.5 kb | None | Causes immune response, short-term expression |
| AAV | < 4.5 kb | Low | Causes immune response |
| Alphavirus | < 7.5 kb | None | Short-term expression |
| Herpesvirus | > 30 kb | None | May cause immune response |
| Retrovirus | < 8 kb | High | Risk of insertional mutagenesis. Just infects dividing cells |
| Lentivirus | 8–10 kb | High | Risk of insertional mutagenesis |
| Vaccinia virus | 25 kb | None | Short-term expression |
Our Services
In recent years, scientific advances in viral vector engineering, rare disease genome identification, and gene editing have ushered in a new era of viral gene therapy. Our company's viral vector development services provide customers with a cost-effective and one-stop solution, including the design and construction of suitable viral vectors as well as the production and purification of viral vectors. We can provide different kinds of viral vector development, including but not limited to:
Adenoviral Vectors
Adeno-Associated Virus Vectors
Lentiviral Vectors
In order to improve the targeting and efficiency of viral vectors, our company also provides adaptor-based viral vector development and genetic incorporation-based viral vector development. In addition to the above viral vector development services, we also provide downstream analysis of viral vectors and other related services to meet your comprehensive requirements in rare disease research. Optional services include but are not limited to:
Viral Vector Development Workflow
Adenoviral Vector Design and Modification
Adenoviral Vector Analysis
Transfection
Virus Titer Examination
Large-Scale Production
With extensive experience in rare disease therapy research and development, our company provides customers with a convenient solution. Our viral vector development service is a simplified workflow by a group of specially trained and professional scientists. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Srivastava, A., et al. "Manufacturing challenges and rational formulation development for AAV viral vectors." Journal of pharmaceutical sciences 110.7 (2021): 2609-2624.
- Maldonado, R., et al. "Curative gene therapies for rare diseases." Journal of Community Genetics 12 (2021): 267-276.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.